Retatrutide has become one of the more closely watched compounds in modern peptide research. Interest has grown particularly around its unusual mechanism, as it is being studied for activity across three different hormone pathways rather than targeting just one or two.
The term GLP-3 is sometimes used informally when referring to retatrutide because of this three-pathway activity. However, retatrutide is not a naturally occurring “GLP-3” hormone. It is an investigational peptide designed to activate receptors associated with GLP-1, GIP and glucagon.
This combination is what makes retatrutide different from better-known compounds such as semaglutide and tirzepatide.
What Is Retatrutide?
Retatrutide is an investigational peptide being developed and studied by Eli Lilly. It is a synthetic molecule designed to act as an agonist at three receptors: GLP-1, GIP and glucagon.
Each of these signalling pathways has a different role in the body.
GLP-1 and GIP are incretin hormones involved in glucose regulation and other metabolic processes, while glucagon has an important role in energy metabolism and maintaining blood glucose levels.
By combining activity at all three receptors, researchers are investigating whether retatrutide can produce a broader metabolic effect than compounds that work through fewer pathways.
Retatrutide is still an investigational compound and should not be confused with an approved treatment simply because it is being studied in clinical trials by Research Peptides.
Why Is Retatrutide Sometimes Called a GLP-3 Peptide?
The name “GLP-3” can be confusing because it may sound like retatrutide is a newly discovered natural hormone.
That is not the case.
The term is generally used as a convenient way to describe retatrutide’s triple-receptor activity. Unlike semaglutide, which primarily targets the GLP-1 receptor, and tirzepatide, which targets GLP-1 and GIP receptors, retatrutide is designed to target:
- GLP-1 receptors
- GIP receptors
- Glucagon receptors
For this reason, retatrutide is often described as a triple agonist.
This three-way mechanism is one of the main reasons the compound has attracted so much interest in peptide and metabolic research.
How Does Retatrutide Work?
To understand retatrutide, it helps to look at the three pathways separately.
GLP-1 Activity
GLP-1, or glucagon-like peptide-1, is an incretin hormone naturally produced in the body.
GLP-1 signalling is involved in several processes, including glucose-dependent insulin secretion, gastric emptying and appetite regulation.
Drugs and research compounds that activate the GLP-1 receptor have therefore become an important area of metabolic research.
Retatrutide includes GLP-1 receptor activity as one part of its overall mechanism.
GIP Activity
GIP stands for glucose-dependent insulinotropic polypeptide.
Like GLP-1, GIP is an incretin hormone. Its receptors are found in tissues throughout the body, and GIP signalling is involved in glucose and energy metabolism.
Tirzepatide was notable because it combines GLP-1 and GIP receptor activity. Retatrutide takes this concept further by adding glucagon receptor activity to the combination.
Glucagon Activity
Glucagon is another naturally occurring hormone, but its role differs from GLP-1 and GIP.
It plays an important role in energy balance and helps regulate blood glucose, particularly during periods when glucose availability is low.
Retatrutide’s glucagon receptor activity is one of the features that separates it from conventional GLP-1 receptor agonists.
Researchers are particularly interested in how glucagon signalling interacts with GLP-1 and GIP activity when all three pathways are activated by the same compound.
Retatrutide vs Semaglutide vs Tirzepatide
One of the easiest ways to understand why retatrutide has received attention is to compare its mechanism with other well-known compounds.
| Compound | Main receptor activity |
| Semaglutide | GLP-1 |
| Tirzepatide | GLP-1 + GIP |
| Retatrutide | GLP-1 + GIP + glucagon |
This does not mean that one compound is automatically “better” than another. They have different pharmacological profiles, and research results need to be interpreted within the context of their individual clinical trials.
The key difference is the number and type of pathways being targeted.
Semaglutide focuses on GLP-1 receptor activity. Tirzepatide combines GLP-1 and GIP activity. Retatrutide adds glucagon receptor activity to the GLP-1/GIP combination.
Why Has Retatrutide Attracted So Much Attention?
There are several reasons retatrutide has become an important subject in metabolic research.
The first is its triple-agonist mechanism. Researchers have been investigating whether simultaneously influencing GLP-1, GIP and glucagon pathways can produce effects that are different from targeting one or two pathways.
The second is the clinical research surrounding the compound. Trials have investigated retatrutide in people with obesity and other metabolic conditions, generating considerable interest in its potential role in future treatments.
Early and later-stage studies have reported substantial changes in body weight and other metabolic measures, although the results of individual trials should not be interpreted as proof that the compound is suitable for personal use.
The third reason is the broader development of incretin-based medicines. Semaglutide and tirzepatide have already demonstrated how strongly the scientific and medical communities are interested in compounds that influence appetite, glucose regulation and metabolic pathways.
Retatrutide represents a different approach within the same broader field.
What Is a Retatrutide GLP-3 Pen?
Retatrutide GLP-3 pen 40mg generally refers to a pen-style delivery format associated with a retatrutide research product.
However, it is important to distinguish the delivery format from the compound itself.
The pen does not make retatrutide a different molecule. The active compound remains retatrutide, while the pen refers to how a particular product may be presented or administered.
Research products can vary considerably in formulation, concentration, packaging and quality. Anyone researching these products should therefore pay attention to the actual product documentation rather than relying only on terms such as “GLP-3 pen”.
Products described for laboratory or research purposes, including those supplied by Research Peptides, should not automatically be assumed to have the same formulation, quality controls or regulatory status as an approved pharmaceutical product.
Is Retatrutide Approved?
Retatrutide remains an investigational compound rather than an approved medication.
This distinction is important.
A compound can generate promising results during clinical research without being approved for routine medical use. Regulatory approval requires extensive evidence regarding efficacy, safety, manufacturing quality and the appropriate conditions for use.
Retatrutide’s ongoing development means researchers are continuing to investigate its effects and safety profile.
Anyone considering a medicine or treatment for a medical condition should discuss appropriate options with a qualified healthcare professional rather than relying on research-product information.
What Are Researchers Studying?
Research involving retatrutide has examined several areas of interest, particularly its effects on body weight and metabolic health.
Researchers are also interested in questions such as:
- How does triple-receptor activity compare with single- and dual-receptor approaches?
- What happens when GLP-1, GIP and glucagon pathways are activated together?
- How does the compound affect glucose and energy metabolism?
- What dosage and treatment schedules are appropriate in clinical development?
- What adverse effects may occur with continued exposure?
- How does retatrutide compare with other emerging metabolic therapies?
These questions are important because the goal of clinical research is not simply to determine whether a compound produces an effect. Researchers also need to understand its safety, tolerability, appropriate dosing and long-term outcomes.
What Makes Retatrutide Different?
The simplest answer is its three-way mechanism.
Semaglutide established a strong research and clinical focus on GLP-1 receptor activity. Tirzepatide expanded the approach by combining GLP-1 and GIP receptor activity.
Retatrutide adds a third component through glucagon receptor activity.
This makes it scientifically interesting because the three pathways influence overlapping but distinct aspects of metabolism.
However, a more complex mechanism does not automatically mean a compound is appropriate for everyone. The actual benefits and risks have to be established through clinical research and regulatory evaluation.
Final Thoughts
Retatrutide is an investigational peptide that has attracted significant attention because of its unique GLP-1, GIP and glucagon receptor activity.
The term “GLP-3” is commonly used informally to describe this triple-action mechanism, but retatrutide itself is the name of the investigational compound.
Compared with semaglutide and tirzepatide, retatrutide represents another step in the development of multi-pathway metabolic research. Its ongoing clinical studies are helping researchers understand how simultaneous activation of these pathways may affect body weight, glucose regulation and broader metabolic processes.
For now, retatrutide should be viewed in the context of scientific research rather than as an established treatment. As additional clinical data become available, researchers and regulators will have a clearer picture of where this compound may fit within the future of metabolic medicine.
